Business Wire

Ant Group Launches AI Healthcare App AQ Amid Push into Healthcare Sector

26.6.2025 17:41:00 EEST | Business Wire | Press release

Share

Ant Group today launched its AI healthcare app, AQ, to accelerate the company’s entry into the healthcare sector. The app helps users manage their daily healthcare needs with over 100 AI-powered services, including doctor recommendations, medical report analysis, and personalized medical advice. It also connects users to digital services from over 5,000 hospitals and nearly 1 million doctors across China.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250626728870/en/

Ant Group launched the AI healthcare app AQ to accelerate its entry into the healthcare sector

By around 2035, over 400 million people, or more than 30% of China’s population, will be aged 60 or older, according to projections from China’s National Health Commission. This demographic shift is expected to significantly increase healthcare demand in the country.

“Ant Group hopes that through AQ, it can provide everyone with a trusted healthcare manager, advancing inclusive healthcare and bringing every Chinese citizen one step closer to a healthier life,” said Cyril Han, CEO of Ant Group.

The AQ app is powered by Ant Group’s Healthcare Large Model, which draws on over a decade of expertise in the healthcare sector. Since 2014, when Ant Group launched its first online hospital appointment-making service on the flagship Alipay digital platform, the company has been supporting the digital and intelligent transformation of China’s healthcare industry.

The Healthcare Large Model, equipped with advanced medical reasoning and multimodal interaction capabilities, has consistently ranked in first place in the HealthBench and MedBench evaluations. Furthermore, it leverages Ant Group’s leading privacy and security technologies to ensure a safe and reliable experience.

Through this model, Ant Group is empowering medical institutions and doctors to offer more efficient, accessible, and personalized services to users with AI-enabled solutions.

Empowering Medical Institutions with Secure and Efficient AI Integration

  • Healthcare Large Model Integration
    In March 2025, Ant Group collaborated with IT industry leaders to integrate its advanced healthcare large model into various types of All-in-One Large Model Machine for Healthcare. This solution allows hospitals to deploy AI models on-premises, ensuring efficient and secure use of AI to optimize daily operations and improve patient services.
  • AI Assistant for Hospital Services
    Ant Group is also helping hospitals develop user-facing applications. Angel, an AI agent developed in collaboration with public medical institutions in China’s Zhejiang Province, has served over 1,000 medical facilities, handling more than 50 million user interactions.
  • AI Medical Insurance Assistant
    Additionally, Ant Group has supported local basic medical insurance institutions across China in developing Yibaoer, an AI agent designed to assist users with medical insurance-related inquiries.

AI-Assisted Diagnosis and Patient Education: Extending Doctor Capabilities Beyond Time and Place Constraints

  • AI Doctor Assistant
    In January 2025, Ant Group completed the acquisition of Haodf, a leading healthcare platform specializing in online doctor consultations. Together, the two sides launched the AI Doctor Assistant, which supports doctors with AI-assisted diagnosis, medical record management, and patient education.
  • AI Doctor Agents
    Ant Group is also collaborating with nearly 200 prominent doctors in China to develop AI Doctor Agents that provide patients with credible, authoritative healthcare advice and medical guidance. This initiative not only empowers individuals to maintain better health but also supports those with limited access to medical resources, ensuring timely, expert care when it’s needed most.

Through these ongoing initiatives, Ant Group is contributing to the more efficient use of limited medical resources, with the aim of supporting greater medical inclusion.

About Alipay

As the world becomes increasingly digital, Alipay has evolved from a trusted e-wallet into an all-in-one digital platform for daily services, connecting more than one billion consumers to over 80 million merchants across China. Alipay offers users a secure, seamless mobile payment experience and integrates over 10,000 services across sectors like travel, healthcare, tourism, and entertainment. With digital tools like Alipay Tap!, mini-programs, lifestyle accounts, Alipay enables merchants, institutions, and independent software vendors (ISVs) to enhance operational efficiency and effectiveness. In addition, Alipay is developing a new AI-driven open platform by integrating AI agents to deliver smarter, more personalized services to its users as well as facilitating the digital transformation of the service sector.

About Ant Group

Ant Group is a global digital technology provider and the operator of Alipay, a leading internet services platform in China, connecting over one billion users to more than 10,000 types of consumer services from partners. Through innovative products and solutions powered by AI, blockchain and other technologies, Ant Group supports partners across industries to thrive through digital transformation in an ecosystem for inclusive and sustainable development. For more information, visit www.antgroup.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20250626728870/en/

Contacts

Media Inquiries
Yinan Duan
globalcomms@antgroup.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

www.businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Strongest Half-Year in Curatis’s History — Revenue up 51% and Significant Progress on Corticorelin (C-PTBE-01)21.9.2026 08:03:00 EEST | Press release

Curatis Holding AG (SIX:CURN, “Curatis”) reports net sales from goods and services of CHF 7.9m for the first half of 2026, up 51% (H1 2025: CHF 5.2m), with the loss for the period narrowing to CHF -0.4m (H1 2025: CHF -1.2m) and cash and cash equivalents rising to CHF 3.6m (31 December 2025: CHF 1.9m). Curatis also advanced its corticorelin (C-PTBE-01) program on multiple levels, including an exclusive Japan licence with Neupharma and continued manufacturing progress. Business development and finances Net sales from goods increased by 46% to CHF 7.4m (H1 2025: CHF 5.0m) and net sales from services rose to CHF 0.6m (H1 2025: CHF 0.2m). Growth was driven both by products marketed for some time and by products added to the distribution portfolio in 2025 and 2026. The gross contribution from goods and services rose by 32% to CHF 1.8m (H1 2025: CHF 1.3m); the combined cost base grew by only 9% against net sales growth of 51%, as personnel expenses rose 5% to CHF 1.3m (H1 2025: CHF 1.2m) and

Galderma Begins Trading in the Swiss Market Index, Joining Switzerland's Leading Blue Chip Companies21.9.2026 08:00:00 EEST | Press release

Galderma (SIX: GALD), the pure-play dermatology category leader, today begins trading as a constituent of the Swiss Market Index (SMI), Switzerland's leading blue chip equity benchmark comprising 20 of the country's largest and most liquid listed companies. Less than three years after its IPO on the SIX Swiss Exchange in March 2024, Galderma has established itself as one of Switzerland's leading listed companies. Its inclusion in the SMI reflects the company's strong growth, disciplined execution and increasing relevance in Swiss and international capital markets as it advances its ambition to become the world's leading dermatology powerhouse. Since its IPO, Galderma has continued to execute its growth-focused integrated dermatology strategy, delivering strong performance across Injectable Aesthetics, Dermatological Skincare and Therapeutic Dermatology. Net sales increased from 4.410 billion USD in 2024 to 5.207 billion USD in 2025, driven by science-led innovation, portfolio and geogr

International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 20:52:00 EEST | Press release

International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he has served as pro bono counsel to five Nobel Peace Prize laureates. The New York Times has referred to him as "The Extractor" for his work freeing political prisoners worldwide. Genser's decision to support Yim Leak's team comes as the businessman faces an asset freeze exceeding 20 billion baht (more than U

Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 18:38:00 EEST | Press release

Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co

Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli ® (Relacorilant)18.9.2026 15:00:00 EEST | Press release

Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye